A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

Recruiting now

Conditions studied: Pancreatic Ductal Adenocarcinoma

In brief

This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combination therapies to patients with KRAS G12R mutated advanced pancreatic ductal adenocarcinoma (PDAC).

Key facts

Study ID

NCT05630989

Run by

Mandana Kamgar, MD

People needed

80

Starts

2023-02-07

Expected to finish

2027-08-01

Last updated by the study team

2026-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years.
• Diagnosis of advanced pancreatic ductal adenocarcinoma as determined by the treating physician or tumor board.
• Tumor must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician.
• Ability to understand a written informed consent document and the willingness to sign it.

You may not qualify if…

• Age <18 years.
• Primary cancer diagnosis other than advanced pancreatic ductal adenocarcinoma
• Tumor does not have a KRAS G12R mutation.

Where it is running

• Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.